PMC:7283670 / 64259-64379 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7283670","sourcedb":"PMC","sourceid":"7283670","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7283670","text":"Experimental; bevacizumab, group:\nbevacizumab 500 mg + 0.9% NaCl 100 ml, intravenous drip\nNo intervention: control group","divisions":[{"label":"p","span":{"begin":0,"end":33}},{"label":"p","span":{"begin":34,"end":89}}],"tracks":[{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T169","span":{"begin":27,"end":32},"obj":"Chemical"},{"id":"T170","span":{"begin":60,"end":64},"obj":"Chemical"},{"id":"T171","span":{"begin":115,"end":120},"obj":"Chemical"}],"attributes":[{"id":"A169","pred":"chebi_id","subj":"T169","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A170","pred":"chebi_id","subj":"T170","obj":"http://purl.obolibrary.org/obo/CHEBI_26710"},{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"subj":"T169","pred":"source","obj":"LitCovid-PD-CHEBI"},{"subj":"T170","pred":"source","obj":"LitCovid-PD-CHEBI"},{"subj":"T171","pred":"source","obj":"LitCovid-PD-CHEBI"}]},{"project":"LitCovid-sentences","denotations":[{"id":"T644","span":{"begin":34,"end":89},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T644","pred":"source","obj":"LitCovid-sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"LitCovid-PD-CHEBI","color":"#e8ec93","default":true},{"id":"LitCovid-sentences","color":"#d693ec"}]}]}}